FY2025 Earnings Estimate for VKTX Issued By Leerink Partnrs

Viking Therapeutics, Inc. (NASDAQ:VKTX) – Stock analysts at Leerink Partnrs cut their FY2025 EPS estimates for Viking Therapeutics in a report released on Thursday, October 23rd. Leerink Partnrs analyst T. Smith now forecasts that the biotechnology company will post earnings per share of ($2.66) for the year, down from their previous estimate of ($2.46). The consensus estimate for Viking Therapeutics’ current full-year earnings is ($1.56) per share. Leerink Partnrs also issued estimates for Viking Therapeutics’ Q4 2025 earnings at ($0.85) EPS, FY2026 earnings at ($3.30) EPS, FY2027 earnings at ($4.77) EPS and FY2028 earnings at ($1.21) EPS.

Viking Therapeutics (NASDAQ:VKTX) last posted its quarterly earnings data on Wednesday, October 22nd. The biotechnology company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.67) by ($0.14). Viking Therapeutics’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the firm posted ($0.22) earnings per share.

Other equities research analysts have also issued reports about the stock. Morgan Stanley increased their target price on shares of Viking Therapeutics from $98.00 to $102.00 and gave the stock an “overweight” rating in a report on Thursday. Cantor Fitzgerald set a $105.00 price objective on shares of Viking Therapeutics in a research report on Thursday. Raymond James Financial dropped their target price on shares of Viking Therapeutics from $125.00 to $122.00 and set a “strong-buy” rating for the company in a report on Thursday, July 24th. Citigroup upped their price objective on Viking Therapeutics from $31.00 to $38.00 and gave the stock a “neutral” rating in a research note on Thursday, July 24th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Viking Therapeutics in a report on Friday. Three equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $85.62.

Viking Therapeutics Stock Up 1.5%

NASDAQ VKTX opened at $34.42 on Monday. Viking Therapeutics has a 52 week low of $18.92 and a 52 week high of $81.73. The company has a market capitalization of $3.89 billion, a P/E ratio of -16.24 and a beta of 0.64. The stock’s 50-day moving average price is $28.57 and its 200-day moving average price is $28.83.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Allworth Financial LP increased its stake in Viking Therapeutics by 58.4% during the second quarter. Allworth Financial LP now owns 955 shares of the biotechnology company’s stock worth $25,000 after acquiring an additional 352 shares during the last quarter. Glass Jacobson Investment Advisors llc purchased a new position in shares of Viking Therapeutics in the 2nd quarter worth approximately $28,000. Quarry LP increased its position in shares of Viking Therapeutics by 1,621.4% during the 1st quarter. Quarry LP now owns 1,205 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 1,135 shares during the last quarter. Elevation Point Wealth Partners LLC purchased a new stake in Viking Therapeutics during the 2nd quarter valued at $29,000. Finally, Avion Wealth lifted its position in Viking Therapeutics by 1,157.0% in the third quarter. Avion Wealth now owns 1,521 shares of the biotechnology company’s stock worth $39,000 after buying an additional 1,400 shares during the last quarter. Hedge funds and other institutional investors own 76.03% of the company’s stock.

About Viking Therapeutics

Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.